Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Operations (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Cash from Operations for 6 consecutive years, with 28551000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 162.25% to 28551000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 109082000.0 through Dec 2025, up 18.95% year-over-year, with the annual reading at 109082000.0 for FY2025, 18.95% up from the prior year.
  • Cash from Operations for Q4 2025 was 28551000.0 at 4D Molecular Therapeutics, up from 46498000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 28551000.0 in Q4 2025, with the low at 47758000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 23763900.0, with a median of 22882000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations crashed 2409.91% in 2024, then soared 162.25% in 2025.
  • Over 5 years, Cash from Operations stood at 21836000.0 in 2021, then dropped by 1.73% to 22214000.0 in 2022, then fell by 10.97% to 24650000.0 in 2023, then crashed by 86.06% to 45863000.0 in 2024, then skyrocketed by 162.25% to 28551000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 28551000.0, 46498000.0, and 43377000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.